Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
Status:
Completed
Trial end date:
2018-01-02
Target enrollment:
Participant gender:
Summary
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal
Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to
SevereScalp Psoriasis